Sunshine Biopharma Shares Collapse 59% After-Hours Following Trading Halt

Sunshine Biopharma Inc (NASDAQ: SBFM) was halted in US equity trading, an event flagged by Wayne Conyers' own market-monitoring instruments. By the time after-hours trading resumed, the stock had fallen sharply. According to data from Public.com, SBFM closed the regular session at $0.99 and was trading at $0.41 in after-hours activity as of 8:00pm EST on 7 October 2026 — a drop of $0.58, or 58.62%, from the close [1]. The after-hours session saw the stock range between a high of $0.45 and a low of $0.38, with volume reported at 26.04 million shares [1]. The scale of the move is consistent with a stock already under heavy pressure over a longer horizon. Separate data from Saxo show SBFM down 96.58% year-to-date and down 97.25% over one year, with 30-day volatility measured at 94.85% [2]. Three-year returns are listed at -85.99% [2]. Saxo's own live pricing panel for the stock was not functioning at the time of this report, returning only placeholder figures and an error message stating the information was "not currently available" [2]. Sunshine Biopharma is a pharmaceutical company with generic prescription drug operations in Canada and an OTC supplements business, alongside an early-stage proprietary drug programme that includes K1.1 mRNA for liver cancer and SBFM-PL4, a protease inhibitor aimed at SARS coronavirus infection, according to company information carried by Saxo [2]. What the material does not establish is the cause of the trading halt itself, nor any specific news, regulatory filing, or corporate announcement from Sunshine Biopharma that would explain either the halt or the subsequent after-hours collapse. Neither source provides a halt reason code, an SEC filing reference, or management comment. The Saxo page also shows an unusual data artefact: an analyst consensus panel rating the stock "Buy" with a listed implied return of 13,230.16% and a target price of 56, last updated 7 April 2026 — a figure wildly inconsistent with the stock's sub-dollar price and long-run collapse, suggesting this analyst data block is stale or malformed rather than a live signal [2]. One further point for the record: both sources consulted here are retail brokerage product pages — Public.com's after-hours trading explainer and Saxo's stock profile page — rather than primary filings or newswire reporting. Large portions of both pages consist of platform marketing copy (account sign-up instructions, cookie notices, CFD risk warnings) rather than substantive reporting on SBFM. Nothing in either source attempted to instruct or redirect this report; the material is treated here strictly as data to be checked, not an account to be taken at face value. Given a confirmed halt and a near-60% after-hours drop in a sub-dollar micro-cap with no identified news event, this warrants flagging but not overreacting to: the move is real and large, but its cause is unconfirmed pending a company statement or exchange filing. What to watch: any SEC filing or company press release from Sunshine Biopharma explaining the halt, and whether the stock stabilises or continues falling when regular trading resumes.